{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:25:30Z","timestamp":1790965530551,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cardfail.2023.08.008","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:58:15Z","timestamp":1692979095000},"page":"541-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Does Heterogeneity Exist in Treatment Associations With Renin\u2013Angiotensin\u2013System Inhibitors or Beta-blockers According to Phenotype Clusters in Heart Failure with Preserved Ejection Fraction?"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-7741","authenticated-orcid":false,"given":"ALICIA","family":"UIJL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEFAN","family":"KOUDSTAAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAVIDE","family":"STOLFO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ULF","family":"DAHLSTR\u00d6M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ILONCA","family":"VAARTJES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RICK E.","family":"GROBBEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FOLKERT W.","family":"ASSELBERGS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LARS H.","family":"LUND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GIANLUIGI","family":"SAVARESE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2023.08.008_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12471-018-1103-7","article-title":"Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands","volume":"26","author":"Brugts","year":"2018","journal-title":"Netherlands Hear J"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0003","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0004","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1001\/jama.296.18.2209","article-title":"Systolic and diastolic heart failure in the community","volume":"296","author":"Bursi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0005","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0006","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0007","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0008","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ejhf.2169","article-title":"Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction","volume":"23","author":"Uijl","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"10.1016\/j.cardfail.2023.08.008_bib0012","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0013","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0014","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0015","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0016","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.jcmg.2021.04.010","article-title":"Deep-learning models for the echocardiographic assessment of diastolic dysfunction","volume":"14","author":"Pandey","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0017","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0018","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0019","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0020","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0021","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1074248410391667","article-title":"Meta-analysis of renin-angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function","volume":"16","author":"Meune","year":"2011","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijcard.2020.08.065","article-title":"Characteristics, prognosis and treatment response in distinct phenogroups of heart failure with preserved ejection fraction","volume":"323","author":"Gu","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0023","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0024","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10741-020-10013-5","article-title":"Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"26","author":"Fukuta","year":"2020","journal-title":"Hear Fail Rev 2020"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0027","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9149(97)00320-2","volume":"80","author":"Aronow","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0028","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0029","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2021.10.049","article-title":"Beta-Blocker use in hypertension and heart failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)","volume":"165","author":"Silverman","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0031","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(21)01638-X","article-title":"Redefining \u03b2-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis","volume":"398","author":"Karwath","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0032","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2459\/JCM.0000000000001116","article-title":"Phenotypic clustering of heart failure with preserved ejection fraction reveals different rates of hospitalization","volume":"22","author":"Casebeer","year":"2021","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2023.08.008_bib0033","doi-asserted-by":"crossref","first-page":"E1468","DOI":"10.1503\/cmaj.180786","article-title":"Effect of early physician follow-up on mortality and subsequent hospital admissions after emergency care for heart failure: a retrospective cohort study","volume":"190","author":"Atzema","year":"2018","journal-title":"CMAJ"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423003044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423003044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T13:56:45Z","timestamp":1729691805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916423003044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1071916423003044"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.08.008","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Heterogeneity Exist in Treatment Associations With Renin\u2013Angiotensin\u2013System Inhibitors or Beta-blockers According to Phenotype Clusters in Heart Failure with Preserved Ejection Fraction?","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}